Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA

Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,898,112 shares of the company’s stock, valued at approximately $6,207,000. Taysha Gene Therapies comprises 3.8% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 8th biggest holding. Ally Bridge Group NY LLC owned approximately 0.69% of Taysha Gene Therapies at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at approximately $157,000. Two Sigma Investments LP increased its stake in shares of Taysha Gene Therapies by 102.3% in the third quarter. Two Sigma Investments LP now owns 66,105 shares of the company’s stock worth $216,000 after buying an additional 33,423 shares during the last quarter. Squarepoint Ops LLC raised its holdings in Taysha Gene Therapies by 97.9% in the third quarter. Squarepoint Ops LLC now owns 198,352 shares of the company’s stock valued at $649,000 after acquiring an additional 98,126 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies in the third quarter valued at $40,000. Finally, UBS Group AG boosted its stake in Taysha Gene Therapies by 144.7% during the 3rd quarter. UBS Group AG now owns 639,356 shares of the company’s stock valued at $2,091,000 after acquiring an additional 378,117 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Raymond James Financial reissued a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies has an average rating of “Moderate Buy” and an average target price of $10.91.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $4.49 on Friday. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $6.02. The company has a market cap of $1.23 billion, a PE ratio of -13.61 and a beta of 1.02. The stock has a 50 day simple moving average of $4.70 and a 200-day simple moving average of $4.50. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Insiders Place Their Bets

In other Taysha Gene Therapies news, CEO Sean P. Nolan sold 136,789 shares of the business’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the transaction, the chief executive officer owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. The trade was a 4.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total value of $942,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $4,740,327.69. The trade was a 16.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by company insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.